Endothelial cells (ECs) are involved in the process of angiogenesis, the outgrowth of new vessels from preexisting blood vessels. If available in sufficiently large numbers, ECs could be used therapeutically to establish blood flow through in vitro engineered tissues and tissues suffering from severe ischemia. Adipose tissue (AT) is an easily available source of large number of autologous ECs. Here we describe the isolation, in vitro expansion, and characterization of human AT derived ECs (AT-ECs). AT-ECs proliferated rapidly through 15-20 population doublings. The cultured cells showed cobblestone morphology and expressed EC markers including CD31, CD144, eNOS, CD309, CD105, von Willebrand factor, CD146, CD54, and CD102. They bound Ulex europaeus agglutinin I lectin and took up DiI-Ac-LDL. The AT-ECs formed capillary-like tubes in Matrigel in vitro and formed functional blood vessels in Matrigel following subcutaneous injection into immunodeficient mice. In conclusion, AT-ECs reach clinically significant cell numbers after few population doublings and are easily accessible from autologous AT, which also contains mesenchymal stem cells/ pericytes. Thus, AT yields two cell populations that may be used together in the treatment of tissue ischemia and in clinical applications of tissue engineering.
INTRODUCTION
human cord blood was described and compared (24) . EPCs from cord blood were found to be superior to adult cells both in proliferative potential and vasculo-Therapeutic strategies based on the delivery of angiogenic cells have been attempted for peripherovascular genesis, but the vasculogenic capacity of both populations deteriorated rapidly with time in cell culture. In disease (40,46) and ischemic heart disease (9) , so far with modest functional improvement. Generation of new another study, endothelial colony-forming cells were isolated from unmanipulated human peripheral blood blood vessels is also a major issue in tissue engineering (20, 32, 39) . Here different approaches have been used to (34) . These cells are easily available, but because the precursor frequency is low, prolonged in vitro cell overcome the problem of vascularization, such as incorporation of angiogenic factors into the engineered expansion will be required in order to get an appropriate number of cells for therapy. tissues to promote the ingrowth of microvessels, prevascularization of matrices prior to cell seeding, and seed-Mature ECs can also be candidates for cell therapy applications. These cells are mostly derived from the ing of endothelial cells (ECs) along with other cell types (27) . However, to date no cell-based therapeutic strategy umbilical vein or the aortic endothelium. Both these populations may be expanded in vitro, although they do has been able to robustly generate new blood vessels in engineered or ischemic tissues. not normally proliferate over many passages (17) . However, in terms of human cell therapy, the main problem The most popular candidates for strategies of cellbased therapeutic neovascularization are the endothelial associated with the use of these cells is that they will always be allogeneic to the patient, and therefore likely progenitor cells (EPCs) (14, 32) . EPCs were first isolated from human peripheral blood by Asahara et al. (2) . Two to be rejected by immunological mechanisms. Microvascular ECs (MVECs) resemble late-outgrowth EPCs (3). distinct EPC populations are observed with different growth characteristics, which are referred to early and As such, they should be promising cells for therapeutic neovascularization. However, MVECs are most com-late-outgrowth EPCs (31) . Recently, the vasculogenic potential of EPCs from adult peripheral blood and monly obtained from sources such as newborn foreskin, the retina, and the myometrium, all sources that in prac-24-40 years) undergoing cosmetic surgery. The donors provided informed consent, and the collection and stor-tical terms will be allogeneic to the patient.
Adipose tissue (AT) is an easily available source of age of AT, AT-ECs, and AT-MSCs were approved by the regional committee for ethics in medical research. large number of autologous cells for cell therapy applications. Mesenchymal stem cells (MSCs) from AT have
The SVF was separated from AT as described previously (4) . Briefly, lipoaspirate (300-600 ml) was been isolated and characterized (4, 49) , and are currently being tested in clinical trials (12) . MSCs are frequently washed repeatedly to remove erythrocytes and leukocytes with Hanks' balanced salt solution (HBSS; Gibco, obtained from the stromal-vascular fraction (SVF) of AT cells. The SVF of AT cells has also been shown to con-Invitrogen, Paisley, UK) containing antibiotics (100 IU/ ml penicillin and 100 IU/ml streptomycin) and 2.5 µg/ tain cells with angiogenic potential (30, 33) . Several attempts have been made to isolate ECs from SVF using ml amphotericin B. This material was then digested for 75 min using 0.1% collagenase A type 1 at 37°C, apply-differential plastic attachment and positive selection strategies (1, 10, 18, 19, 37) . However, there is still a need ing constant gentle rotation. Following centrifugation at 400 × g for 10 min at room temperature the pellet was for data on the phenotype of the AT-EC population, and how the phenotype and gene expression of this cell pop-resuspended in HBSS containing antibiotics and 2% fetal bovine serum (FBS; BioWhittaker, Lonza, Ver-ulation is modulated by in vitro culture. These data, combined with experiments showing that the cells are viers, Belgium), and the cells were filtered through 100µm and then 40-µm cell sieves (Becton Dickinson, San able to form vessels in vivo, are required before AT-ECs may be accepted for clinical trials of EC transplantation.
Jose, CA). SVF cells were obtained from the interface after Lymphoprep gradient separation (Axis Shield, Oslo, Here we describe the isolation, purification, expansion, and extensive characterization, both at the uncul-Norway) at 400 × g for 30 min, washed, and resuspended in HBSS containing antibiotics and 2% FBS. Cell counts tured and cultured stage, of the EC population obtained from the SVF from AT. Based on our previous observa-and viability assessment were performed using acridine orange/ethidium bromide staining and a fluorescence tion that most of the AT-ECs did not express CD44, while the majority of AT-MSCs did express this marker microscope (Eclipse E600, Nikon, Kanagawa, Japan).
To obtain AT-ECs from the SVF, CD44 + cells were (4), we chose to purify the AT-ECs from the SVF by removing CD44 + cells. We demonstrate that AT-ECs removed using Dynabeads (Dynabeads Pan Mouse IgG, Invitrogen Dynal AS, Oslo, Norway) according to the have endothelial morphology and phenotype, that they form capillary-like tubes in Matrigel in vitro and func-manufacturer's description. Briefly, Dynabeads were washed, then precoated with monoclonal anti-CD44 tional blood vessels in vivo. One important aspect of these cells, which separates them from other ECs, is that antibody (Caltag Laboratories, Invitrogen, Carlsbad, CA) at the concentration of 0.6 µg antibody per 25 µl they derive from a source that is easily accessible in all patients. They can be obtained in very large numbers, Dynabeads and incubated for 2 h with gentle tilting and rotation. Dynabeads were then washed again and which means that clinically relevant numbers of cells can be obtained after only a few population doublings approximately 400 × 10 6 magnetic CD44 beads were added to 100 × 10 6 SVF. in vitro. Importantly, they derive from a tissue that also yields MSCs (4, 49, 50) . Recent studies on MSC popula-In Vitro Expansion of AT-ECs tions suggest that these derive from blood vessel walls and that they may in fact be identical to the pericytes AT-ECs were plated at 2 × 10 6 cells per 75-cm 2 tissue culture flask (Nunc, Roskilde, Denmark) coated with 1% (5-7). Small blood vessels are composed of ECs surrounded by basal lamina and loosely covered by peri-gelatin. Cells were maintained at 37°C in an atmosphere of 5% CO 2 in humid air using EC growth medium cytes, which are embedded in the basement membrane of the microvessels underlying the ECs (23, 38, 41) . The (MCDB 131; Gibco) supplemented with 7.5% FBS, 1% L-glutamine, 1 ng/ml basic fibroblast growth factor, 1 pericytes play a role in vascular stabilization by interaction with ECs (42) and can stimulate angiogenesis µg/ml hydrocortisone, 10 ng/ml epidermal growth factor, 50 µg/ml gentamicin, and 250 ng/ml amphotericin (26, 45) . Thus, AT may provide two cell populations required for vasculogenesis.
B. Cells still in suspension were removed on day 4-5 and the medium was replaced. When the cells reached MATERIALS AND METHODS 80-90% confluency, cell adherence was interrupted by trypsin-ethylenediaminetetraacetic acid (EDTA) solution All reagents were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise stated.
for ECs and the cells were inoculated into new flasks at 10,000 cells/cm 2 . Additional purging of contaminating Isolation of AT-ECs cells was performed using anti-CD44-coated Dynabeads if required at the first passage. Cells were routinely pas-AT was obtained from liposuction material from abdominal regions of three healthy female donors (age saged every 3-4 days. Viable cells were counted at each passage. Growth curves were generated using GraphPad Prism version 5 software. As a positive control, primary adult human dermal MVECs (P6) were purchased from Prism version 5 software (GraphPad Software Inc., La Jolla, CA).
PromoCell GmbH (Heidelberg, Germany). Human AT-MSCs and chondrocytes were used as negative controls Isolation and In Vitro Expansion of AT-MSCs for the endothelial phenotype. To obtain AT-MSCs/pericytes for the Matrigel vas-Flow Cytometry cularization studies the CD44 + cells positively selected from the SVF of the same donors were cultured in Flow cytometry was performed for determination of cell surface antigen expression of freshly isolated (uncul-Dulbecco's modified Eagle's medium/F12 (Gibco) containing 10% FBS and antibiotics. To remove remaining tured) and cultured (P2, P6, and P12) AT-ECs from three different donors and of human dermal MVECs (P6). All CD45 + leukocytes, at P2, magnetic beads directly coupled to mouse anti-human CD45 monoclonal antibodies monoclonal antibodies are provided in Table 2 . Irrelevant control antibodies were included for each of the different (Caltag Laboratories), as described above, were mixed with the CD44-depleted cells at a ratio of 4 beads/cell. fluorochromes. Cells were incubated with directly conjugated antibodies for 10 min, washed with phosphate-After 2 h of incubation the CD45 + cells attached to beads were removed using a magnet, and the remaining buffered saline (PBS) containing 1% FBS, and fixed in 1% paraformaldehyde (PFA). Cells were analyzed using cells were placed back in cell culture for further in vitro expansion.
a FACSCalibur flow cytometer applying BD CellQuest Pro Software (BD Biosciences).
Characterization of AT-ECs
Intracellular Staining for von Willebrand Factor The isolated AT-ECs from all the three donors were characterized at the uncultured stage (P0), at early (P2), Flow cytometry was performed for determination of intracellular expression of von Willebrand factor (vWF) middle (P6), and late (P12) passages. The endothelial nature of the cells was confirmed by real-time reverse in freshly isolated (uncultured) and cultured (P2, P6, and P12) AT-ECs from three different donors. For intracel-transcription-polymerase chain reaction (RT-PCR), flow cytometry, Ulex europaeus agglutinin I lectin (UEA-1) lular staining, a BD Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences) was used according to binding, and DiI complex acetylated low-density lipoprotein (DiI-Ac-LDL) uptake as well as in vitro and in the manufacturer's description. Briefly, cells were trypsinized, washed, centrifuged, and then resuspended in vivo angiogenesis assays.
BD Cytofix/Cytoperm buffer. After 20-min incuba-Real-Time RT-PCR Analysis tion cells were washed in 1× BD Perm/Wash buffer and incubated for 30 min on ice with mouse anti-Total RNA was extracted from cells at different passages using RNAqueous-Micro Kit (Applied Biosystems/ human vWF (Immunotech, Marseille, France). Cells were washed once again, incubated for 30 min on ice Ambion, Austin, TX) according to the manufacturer's protocol and treated with DNase I (Applied Biosystems/ with goat anti-mouse Ig (H+L)-R-Phycoerythrin (RPE) (Southern Biotech), washed, and finally fixed with 1% Ambion). Reverse transcription (RT) was performed using High-Capacity cDNA Reverse Transcription Kit PFA and analyzed by a FACSCalibur flow cytometer applying BD CellQuest Pro Software. As a negative (Applied Biosystems, Foster City, CA) following the manufacturer's protocol with 200 ng total RNA/20 µl control secondary antibody alone was used to assess nonspecific fluorescence. RT reaction. Relative quantification was performed using the 7300 Real-time RT-PCR system (Applied Bio-
DiI-Ac-LDL Uptake systems) and TaqMan Gene Expression Assay (Applied Biosystems) reagents according to the manufacturer's
To assess the uptake of DiI-Ac-LDL (Molecular Probes, Invitrogen, Eugene, OR), AT-ECs and AT-MSCs description. The thermocycler parameters were 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C
were seeded on gelatin-coated chamber slides (BD Falcon 4.0 cm 2 /chamber, BD Biosciences). After reach-for 1 min. All primers are provided in Table 1 . All samples were run in triplicate. After verifying the stable ing confluence, cells were washed once with medium then incubated in medium containing 15 µg/ml of DiI-expression of CDKN1A, this gene was selected as endogenous control. The mRNA levels were normalized Ac-LDL for 4 h in a culture incubator at 37°C with 5% CO 2 . Then the cultures were washed with PBS and cells to the expression of CDKN1A for each sample. Relative mRNA levels were calculated by the comparative CT were fixed in 4% PFA. After fixation cells were washed again. Human chondrocytes were used as a negative con-method, where the threshold cycle (CT) values are given by the 2 −∆∆Ct formula (22). Differential expression of all trol. All immunocytochemistry and immunohistochemistry slides were mounted with Vectashield mounting medium markers was calculated in relation to the corresponding uncultured cells. Graphs were created with GraphPad for fluorescence containing 4′,6-diamidino-2-phenylindole (FITC) conjugated UEA-1 at 1:200 was performed together with the secondary antibody incubation step. As a control, secondary antibody alone was used to assess In Vitro Tube Forming Assay nonspecific fluorescence. Because AT-ECs are abundant within the SVF, even and mixed with AT-ECs were also tested in this assay.
after purging of non-endothelial cells, we could obtain Cultures were incubated at 37°C in a humidified incuba-15-60 × 10 6 cells from 300-600 ml liposuction matetor with 5% CO 2 for 16-20 h. The presence of tubes rial, of which 8-10 × 10 6 were seeded for further analywas visualized using a Leica DMIL inverse microscope sis. Cell yield was 67.2 × 10 3 ± 20.3 × 10 3 (mean ± SEM) (Leica Microsystems, Wetzlar, Germany). The assay cells/ml of lipoaspirate. was performed in triplicates. PKH67 Fluorescent Cell AT-EC colonies emerged after 4-5 days in the cul-Linker Kit was used to label the cells for the fluoresture. The cultures exhibited the classical EC cobblestone cence image. Images were taken with a Leica DFC 320 morphology from P1 and maintained their morphologicamera (Leica Microsystems) using Adobe Photoshop cal characteristics for as long as cell proliferation con-7.0 software. tinued (Fig. 1A) . AT-ECs quickly entered a phase of logarithmic growth (Fig. 1B) . During this phase, the In Vivo Vasculogenesis Assay population doubling time was 2.3 days. The proportion AT-ECs from donor 2 at 0.3 × 10 6 , 0.5 × 10 6 , and 2 × of AT-ECs that were able to attach and form colonies 10 6 , alone or combined with AT-MSCs from the same was difficult to quantify. However, when the cells were donor (4:1 ratio), were resuspended in 50 µl PBS, mixed passaged for the first time, after 8 days, the cell number with 200 µl of Matrigel on ice, and injected subcuwas unchanged (two donors) and doubled (one donor). taneously into 8-week-old nonobese diabetes/severe Considering the population doubling time, this suggests combined immunodeficiency (NOD/SCID) mice. Each that approximately half of the cells attached and formed experimental condition was performed with two mice.
colonies. Logarithmic growth ceased for cells from two Animal experiments were approved by the National Anidonors at P14, and for one donor at P19. mal Research Authority.
Gene Expression in AT-ECs The Matrigel plugs were removed after 6 weeks, fixed in 10% PFA (Electron Microscopy Sciences,
The endothelial nature of these cells was examined in a number of different ways. Figure 2 shows the Hatfield, PA) overnight, embedded in paraffin, and sectioned. For evaluation of the angiogenic potential, 3-µm-expression of genes relevant to the endothelial lineage and to the mesenchymal lineage, as AT-MSCs were also thick sections were stained for morphological evaluation using hematoxylin and eosin (data not shown). For present in SVF and could be contaminating the AT-ECs. The expression of these genes was calculated relative to immunohistochemistry analysis sections were deparaffinized and then boiled in PBS containing 0.05% the expression of the endogenous control gene CDKN1A.
Relative to the expression in uncultured AT-ECs, the citraconic anhydride (pH 7.4) for 20 min for epitope retrieval. Mouse anti-human CD31 primary antibody at mRNA levels for platelet endothelial cell adhesion molecule-1 (PECAM1), vascular endothelial cadherin (CDH5), 1:20 (DAKO) was applied overnight in a humidified chamber at 4°C diluted in PBS containing 1.25% bovine vascular endothelial growth factor receptor 2 (KDR) and 240 SZÖ KE, BECKSTRØM, AND BRINCHMANN
Flow Cytometry Analysis
To examine the efficiency of our isolation technique and possible phenotypic changes due to in vitro expansion, flow cytometry analysis was performed. Figure 4A shows the distribution of the CD31 + , CD44 + , CD45 + , and CD90 + cell populations in the SVF. Figure 4B shows that after the removal of CD44 + cells from the SVF, 4% of CD44 + cells remained in the cell suspension. Of the CD44 − cells, 80% were CD31 + and 87% were CD90 + . However, despite the low proportion of CD44 + cells present after the initial isolation, some of the cultured cells appeared as fibroblastoid toward the first passage. Therefore, to minimize the contamination by non-endothelial cells, we repeated the removal of CD44 + cells at the first passage. This resulted in a >95% CD31 + endothelial cell culture with <2% CD44 + cells contaminating the AT-EC culture at P2. In the course of cell culture, an increasing proportion of the AT-ECs expressed CD44, so that for this donor, 77% of the cells were CD44 + at P12, despite retaining cobblestone morphology and being almost uniformly CD31 + . This observation was made for cells from all the donors, and substantiated the increasing expression of CD44 mRNA shown in Figure 2 .
Of the uncultured CD31 + cells, 90% were also strongly CD90 + . However, the surface expression of CD90 was quickly lost, so that at P2 hardly any surface expression of CD90 was observed for any of the donors (Fig. 4B ). Interestingly this was not a reflection of the the donors, and reduced at P6 and P12 for the last donor. Figure 5 shows that uncultured AT-EC express endothelial markers such as CD34, CD144, CD146, CD105, human lymphocyte antigen (HLA) DR, CD54, CD102, von Willebrand factor (VWF) were uniformly upregulated in cultured cells at P2, and then remained stably vWF, and UEA-1. The expression of most of these molecules was high and persistent in the cultured cells. expressed. CD34, CD90 (THY1) and endothelial nitric oxide synthase (NOS3) showed some between-donor However, for HLA DR the expression disappeared at P2, and for CD144 there was a tendency to reduced variation, but the trend was for an overall relatively stable expression of these genes. The mRNA expression expression in cultured cells. Interestingly this observation, too, was in contrast to the changes observed for levels of the endothelial lineage genes in the cultured AT-ECs were similar to the commercially available CD144 (CDH5) at the mRNA level, where expression was higher in the cultured cells (Fig. 2) . AT-ECs were human MVECs whereas the expression levels of THY1 and CD44 were higher in the AT-ECs (Fig. 3A) . In human uniformly negative for CD133/1 and CD133/2, which have been used as markers for EPCs (3). They expressed chondrocytes, which were used as a negative control, endothelial markers PECAM1, CD34, NOS3, CDH5, moderate levels of VEGFR-1 and VEGFR-2 at the uncultured state. The expression of VEGFR-1 was KDR, and VWF were not expressed. However, CD44 and THY1 were expressed at high levels (data not shown).
reduced or absent in the cultured cells, while VEGFR-2 was upregulated both at the protein and the mRNA level marker expression between the two cell populations. The MVECs did not express CD44 during the culture, in these cells. The cells were negative at all times for the hematopoietic surface antigens CD45, CD14, CD19, whereas CD34 was expressed on the surface of a proportion of the cells. and CD3 (data not shown).
Human dermal MVECs were used as a positive con-DiI-Ac-LDL Uptake trol for the examination of the endothelial and mesenchymal cell surface antigen expression ( Fig. 3C ). As Figure 6 shows that AT-ECs take up DiI-Ac-LDL (Fig. 6A ). This characteristic is common for ECs and expected there were some differences in the surface further indicates the endothelial properties of the cultured cells. Human chondrocytes and AT-MSCs did not take up DiI-Ac-LDL ( Fig. 6B, C, respectively) .
In Vitro and In Vivo Vasculogenesis Assays
The freshly isolated cells did not form vascular tubes when seeded on Matrigel (Fig. 7A) , while the cultured cells both at early (Fig. 7B, C) and late passage (Fig.  7D) formed capillary-like structures, similar to the commercially obtained MVECs (Fig. 3B ). AT-MSCs alone (Fig. 7E) or AT-MSCs mixed with AT-ECs (Fig. 7F) formed single tube-like structures, but not the extensive vascular network formed by the AT-ECs alone.
To determine if AT-ECs could form functional blood vessels in vivo, 0.3 × 10 6 , 0.5 × 10 6 , and 2 × 10 6 of AT-ECs were mixed with Matrigel and implanted into NOD/ SCID mice. In addition, because MSCs have been shown to be identical to pericytes in vivo and thus might improve the vasculogenic properties of the AT-ECs, AT-MSCs from the same donor were mixed into the Matrigel in half of these experiments. The implants were removed and evaluated at 6 weeks. Where AT-ECs were applied at 0.5 × 10 6 and 2 × 10 6 per Matrigel, either alone or combined with AT-MSCs, tubular vessel-like structures could be identified (Fig. 8) . The degree of vascular network formation tended to be greater when combined cell populations were applied. The vessels were human-derived, as they stained with antibodies specifically recognizing human CD31 and UEA-1 ( Fig.  8A-F) . The presence of mouse red blood cells in the lumen indicates that functional capillary networks were formed between the host vasculature and the humanspecific luminal structures created by the implanted cells. Injection of the Matrigel alone resulted in no vascular network formation (data not shown). The specificity of the human CD31 antibody and UEA-1 lectin was confirmed by negative staining of mouse aorta (data not shown).
DISCUSSION
Tissue neovascularization may in itself treat diseases such as myocardial and peripherovascular ischemia, and it is increasingly recognized as an essential ingredient for the successful engineering and transplantation of paradigm was established with the identification of EPCs (2). Human EPCs can be isolated from the blood bone, liver, and a range of other tissues (11, 27, 28, 32, 36, 44, 47) . Neovascularization will not occur in the absence and expanded to clinically relevant numbers, but this requires extended in vitro culture (24, 34) . Recently, of ECs. Classical sources of human ECs have been umbilical vein (HUVEC) and MVECs from foreskin MSCs have been identified as important for neovascularization because they seem to have a role as pericytes (8, 15, 16) . However, in a therapeutic setting these cells will almost always be allogeneic to the patient. A new in most tissues (7) . Thus, the establishment of robust tissue vascularization may require at least two cell types: also of ECs. AT-ECs, too, can be obtained in large numbers as primary uncultured cells, and they, too, are ECs and MSCs/pericytes. We have previously purified and characterized MSCs from AT, and have shown how readily expanded in vitro. The negative selection strategy allows the isolation of AT-ECs with high purity, they can be obtained as primary uncultured cells in large numbers (4) . The present study identifies AT as a source and with no contamination in the cell culture of the immunobeads used for selection. As AT is easily obtain-obtained from late passages, suggesting that the AT-ECs retain their functional capacity better than cord blood-able from all patients, an autologous source of the most important cells required for vasculogenesis should now derived EPCs, which were found to lose functional capacity upon in vitro passaging (24) . To our surprise, be readily available in most therapeutic situations.
It is a little difficult to place the AT-ECs within the uncultured AT-ECs did not form tubes in Matrigel in vitro. To the best of our knowledge, this assay has not established EC hierarchy. As they do not express either isoform of CD133, and do express CD144 (VE-cadherin) been performed on any population of uncultured ECs before, presumably because the different primary ECs and vWF, they are not early EPCs (13, 43) . At the other end of the hierarchy, human MVECs have been shown populations described to date have been too few to perform assays of this nature. While it is likely that the AT-to strongly express CD141 (3), which was only weakly or not expressed on the cells characterized here. AT-ECs, given the right stimulus, would be able to create new vessels in vivo, the in vitro vasculogenesis assay ECs most resemble late EPCs based on the phenotype CD34 + CD133 − vWF + CD144 + VEGFR-2 + eNOS + CD31 + (13, presented here may be able to elicit vasculogenic properties only from the in vitro cultured ECs to which it has 43). However, if almost unlimited in vitro expansion potential is required for cells to deserve the "progenitor" been adapted. Results from the in vivo blood vessel forming assay showed that AT-ECs alone were able to designation, then the AT-ECs are not EPCs. This was shown by Melero-Martin et al. to be a property of form vessels containing mouse-derived erythrocytes. However, these results were inconsistent, and in all human blood-derived endothelial progenitor cells (24) . In contrast, our AT-ECs ceased to proliferate after [14] [15] [16] [17] [18] [19] cases the vessel formation was denser and more consistent when AT-MSCs were added to the Matrigel. More passages. Consequently, these cells are most likely differentiated ECs with high in vitro proliferative capacity.
experiments must be performed, perhaps also using in vivo ischemia models of neovascularization, in order to Although we were able to isolate high numbers of primary AT-ECs, in vitro expansion was necessary to support these observations with statistics. It makes sense, though, to think that addition of pericytes to ECs obtain the number of cells that will likely be needed in most protocols of in vivo vasculogenesis (21,25,29, will yield more robust blood vessels. After all, these cultured cells probably derive from the very cells that made 35, 48) . For instance, 10 8 cells could be obtained after only a few passages. At this time the cells were in a log up the layers of the walls of the small vessels in the AT from which they were isolated (6, 42) . Hopefully this phase of growth and showed the classical cobblestone morphology, but certain changes had already been combination of autologous cells may, in the future, be shown to provide blood supply to ischemic tissues in induced by in vitro culture. On the cell surface, CD34, CD90, and HLA-DR had quickly disappeared. Interest-vivo or a vascular network for in vitro engineered tissue implants. ingly, CD34 and THY1 (CD90) mRNA were maintained for some time after the cell surface expression was lost, ACKNOWLEDGMENTS: The authors thank Colosseum Klinisuggesting that these phenotypes might possibly be kken, Oslo (Tone Irene Langslet) for kindly providing liposuction material, Linda T. Dorg and Finn P. Reinholt for induced under other culture conditions. For comparison, sectioning and H&E staining, Peter Hofgaard and Bjarne CD90 and HLA-DR were also found not to be expressed Bogen for help with the animal experiments, Axel M. Küchler on blood-derived human EPCs, while CD34 was reported for helpful suggestions pertaining to immunohistochemistry, to be expressed on these cultured cells (24, 34) . Equally and Steven Hoel for advice, support and discussions. This strikingly, CD44 changed from being practically absent work was supported by a Storforsk grant from the Norwegian Research Council. The authors declare no competing finanon the uncultured AT-ECs, which were depleted for cial interest.
CD44-expressing cells, to being gradually more expressed. The depletion procedure was sufficiently efficient to REFERENCES strongly suggest that this was a bona fide change in phe- 
